User profiles for A. Fagan

Abigail Fagan

Associate Professor, U. of Florida
Verified email at ufl.edu
Cited by 8952

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

RJ Perrin, AM Fagan, DM Holtzman - Nature, 2009 - nature.com
Alzheimer's disease affects millions of people around the world. Currently, there are no
treatments that prevent or slow the disease. Like other neurodegenerative diseases, Alzheimer's …

[HTML][HTML] Current state of Alzheimer's fluid biomarkers

…, MM Bednar, T Bittner, J Cummings, AM Fagan… - Acta …, 2018 - Springer
Alzheimer’s disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to increase…

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease

K Blennow, B Dubois, AM Fagan, P Lewczuk… - Alzheimer's & …, 2015 - Elsevier
Several potential disease-modifying drugs for Alzheimer's disease (AD) have failed to show
any effect on disease progression in clinical trials, conceivably because the AD subjects are …

Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on …

…, LA Beckett, DA Bennett, S Craft, AM Fagan… - Alzheimer's & …, 2011 - Elsevier
The pathophysiological process of Alzheimer’s disease (AD) is thought to begin many years
before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a …

[HTML][HTML] Clinical and biomarker changes in dominantly inherited Alzheimer's disease

…, C Xiong, TLS Benzinger, AM Fagan… - … England Journal of …, 2012 - Mass Medical Soc
Background The order and magnitude of pathologic processes in Alzheimer's disease are
not well understood, partly because the disease develops over many years. Autosomal …

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans

AM Fagan, MA Mintun, RH Mach, SY Lee… - Annals of …, 2006 - Wiley Online Library
Objectives Amyloid‐β 42 (Aβ 42 ) appears central to Alzheimer's disease (AD) pathogenesis
and is a major component of amyloid plaques. Mean cerebrospinal fluid (CSF) Aβ 42 is …

Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction

…, MG Harrington, TLS Benzinger, AM Fagan… - Nature medicine, 2019 - nature.com
Vascular contributions to cognitive impairment are increasingly recognized 1 , 2 , 3 , 4 – 5 as
shown by neuropathological 6 , 7 , neuroimaging 4 , 8 , 9 , 10 – 11 , and cerebrospinal fluid …

APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline

…, MG Harrington, TLS Benzinger, AM Fagan… - Nature, 2020 - nature.com
Vascular contributions to dementia and Alzheimer’s disease are increasingly recognized 1 ,
2 , 3 , 4 , 5 – 6 . Recent studies have suggested that breakdown of the blood–brain barrier (…

Human apoE isoforms differentially regulate brain amyloid-β peptide clearance

…, RB DeMattos, BW Patterson, AM Fagan… - Science translational …, 2011 - science.org
The apolipoprotein E (APOE) ε4 allele is the strongest genetic risk factor for late-onset,
sporadic Alzheimer’s disease (AD). The APOE ε4 allele markedly increases AD risk and …

APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging

JC Morris, CM Roe, C Xiong, AM Fagan… - Annals of …, 2010 - Wiley Online Library
Objective To examine interactions of apolipoprotein E (APOE) genotype with age and with
in vivo measures of preclinical Alzheimer disease (AD) in cognitively normal aging. Methods …